文献速递垂体与肾上腺疾病

库欣综合征生化控制前后情绪与生活质量的前瞻性评估

Prospective Assessment of Mood and Quality of Life in Cushing Syndrome Before and After Biochemical Control.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

该前瞻性观察研究纳入67例内源性库欣综合征患者(60例垂体、7例肾上腺),在活动期及生化控制后评估生活质量、抑郁和焦虑。治疗使所有领域平均评分显著改善,但仅约半数至三分之二患者达到最小重要差异。症状持续<3年、随访LNSC正常和术后氢化可的松替代>6个月等因素预测改善。

要点

  • 库欣综合征有效治疗后生活质量、抑郁和焦虑平均评分显著改善。
  • 仅52.8%-67.9%患者达到最小重要差异,临床显著恢复不完全。
  • 症状<3年、随访LNSC正常和术后氢化可的松>6个月预测更好改善。

核心结论

  • 有效治疗改善库欣综合征患者情绪和生活质量,但临床显著恢复存在变异性且部分患者不完全。
  • 需限制诊断延迟并提供包括皮质醇昼夜节律正常化在内的综合治疗后护理。

研究设计与样本

  • 前瞻性观察研究,三级中心,纳入67例内源性库欣综合征患者(60例垂体、7例肾上腺)。
  • 在活动期及通过手术和/或药物达到生化控制后评估患者报告结局。

主要发现

  • 治疗使所有领域平均评分改善:QoL +18.2 ± 20.9,BDI-II -6.8 ± 8.6,STAI-状态 -9.6 ± 12.5,STAI-特质 -8.6 ± 12.6,均P < .001。
  • 达到最小重要差异的比例:QoL 64.6%,BDI-II 67.9%,STAI子量表53.2%和52.8%。
  • QoL改善预测因素:较低基线BMI、治疗前症状<3年、术后氢化可的松替代>6个月、随访LNSC正常。
  • 抑郁改善预测因素:症状<3年、随访LNSC正常、手术治疗。
  • 焦虑改善预测因素:较年轻年龄、术后氢化可的松>6个月。

临床怎么用

  • 应尽早诊断以减少症状持续时间,从而改善治疗后生活质量和情绪结局。
  • 治疗后需监测并正常化深夜唾液皮质醇,并关注术后氢化可的松替代时长。
  • 对库欣综合征患者进行长期情绪和生活质量评估,关注未达到临床显著改善者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Cushing's syndrome (CS) impairs quality of life (QoL) and mood. Prospective real-life data on posttreatment recovery and predictors of improvement are limited. OBJECTIVES: Evaluate changes in QoL, depression, and anxiety in patients with CS, before and after biochemical control, and identify predictors of clinically meaningful improvement. DESIGN AND SETTING: Prospective observational study at a tertiary center. PATIENTS: Sixty-seven patients with endogenous CS (60 pituitary, 7 adrenal) were assessed with active disease and again after achieving biochemical control through surgery and/or medication. OUTCOMES: Patient-reported outcomes included CushingQoL, Beck Depression Inventory-II (BDI-II), and State-Trait Anxiety Inventory (STAI). RESULTS: Mean and longest follow-up was 2.3 and 11.5 years, respectively. Treatment led to improvements in mean scores across all domains (QoL: +18.2 ± 20.9, BDI-II: -6.8 ± 8.6, STAI-State: -9.6 ± 12.5, STAI-Trait: -8.6 ± 12.6; all P < .001). However, a minimal important difference was achieved in 64.6% for QoL, 67.9% for BDI-II, and 53.2% and 52.8% for STAI subscales. After multivariable analysis, QoL improvements were predicted by lower baseline body mass index, pretreatment symptoms <3 years, postoperative hydrocortisone replacement >6 months, and normal follow-up late-night salivary cortisol (LNSC). Depression improvements were predicted by symptoms <3 years, normal follow-up LNSC, and surgical treatment. Anxiety improvements were predicted by younger age and >6 months postoperative hydrocortisone. Depression improved more gradually than QoL and anxiety. CONCLUSION: Although effective treatment improves mood and QoL in CS, clinically meaningful recovery is variable and incomplete for some patients. Our findings highlight the need to limit diagnostic delay and provide comprehensive posttreatment care that includes normalization of cortisol circadian rhythm.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Theodorou A, Tan EC, Bakkar MA, et al. Prospective Assessment of Mood and Quality of Life in Cushing Syndrome Before and After Biochemical Control. J Clin Endocrinol Metab. 2026. PMID: 41168092. doi:10.1210/clinem/dgaf598

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。